RECRUITINGOBSERVATIONAL
Impact of Endo-vac Therapy for Esophago-jejunal Anastomotic Leak
Prospective Observational Study on Endo-vac Therapy for Esophago-jejunal Anastomotic Leak
About This Trial
The goal of this observational study is to assess the impact of endoscopic vacuum therapy in patients who underwent total gastrectomy due to gastric cancer and developed esophago-jejunal anastomotic leakage. The main outcomes to be investigated are the following: Primary endpoint: mortality rate Secondary endpoints: morbidity rate, time from AL diagnosis to discharge, patients satisfactory rate.
Who May Be Eligible (Plain English)
Who May Qualify:
- patients who developed esophago-jejunal anastomotic leak less than 50% of circumference of anastomosis
- patients who developed esophago-jejunal anastomotic leak and remained stable at the moment of diagnosis with no indications for diversion surgery
Who Should NOT Join This Trial:
- unstable patients who developed esophago-jejunal anastomotic leak
- patients who developed esophago-jejunal anastomotic leak more than 50% or anastomotic circumference
- patients who rejected endoscopic vacuum therapy
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* patients who developed esophago-jejunal anastomotic leak less than 50% of circumference of anastomosis
* patients who developed esophago-jejunal anastomotic leak and remained stable at the moment of diagnosis with no indications for diversion surgery
Exclusion Criteria:
* unstable patients who developed esophago-jejunal anastomotic leak
* patients who developed esophago-jejunal anastomotic leak more than 50% or anastomotic circumference
* patients who rejected endoscopic vacuum therapy
Locations (1)
National Cancer Institute
Kyiv, Ukraine